DEF: Prime Medicine Seeks Shareholder Approval for Broad Stock Option Repricing Amidst Significant Stock Decline

Prime Medicine, Inc. is seeking stockholder approval for a one-time repricing of certain outstanding stock options for employees and directors, aiming to restore incentive value following a substantial decline in its common stock price.

Summary

• A Special Meeting of Stockholders will be held virtually on August 1, 2025, at 1:00 p.m. Eastern Time.
• The primary purpose of the meeting is to approve a one-time repricing of certain outstanding stock options (Option Repricing Proposal) granted under the company's 2019 and 2022 Stock Option and Incentive Plans.
• The repricing covers up to 8,285,387 shares underlying eligible options, which were granted from August 4, 2021, through March 1, 2025, with original exercise prices ranging from $2.52 to $18.22 per share.
• If approved, the per share exercise price of eligible options will be reduced to the greater of $2.42 (the exercise price of annual option grants made in March 2025) or the closing trading price on The Nasdaq Global Market on the effective date of stockholder approval (the Repricing Date).
• The repriced exercise price will revert to the original price if the option is exercised before a specified Retention Date (one-year for non-executive employees, 18-months for executive officers and directors), if service is terminated for cause, or if the optionholder resigns (unless for good reason).
• The company's common stock experienced significant volatility, declining from a high of approximately $9.39 on February 27, 2024, to a low of approximately $1.15 on April 8, 2025. The closing price on June 30, 2025, was $2.47.
• Many existing options are 'underwater,' with exercise prices for non-executive employees, executive officers, and non-employee directors being 39.68% to 637.65%, 48.58% to 637.65%, and 210.93% to 588.26% above the June 30, 2025, fair market value of $2.47, respectively.
• The Board of Directors recommends voting FOR the Option Repricing Proposal and FOR a proposal to adjourn the Special Meeting if necessary to solicit additional proxies.
• As of the record date, 134,496,013 shares of common stock were issued and outstanding, with each share entitled to one vote.

Sentiment

Score: 4

Explanation: The document addresses a negative situation (significant stock price decline leading to underwater options) with a proposed corrective action (option repricing). While the repricing aims to be positive for employee retention and future alignment, the underlying need for it reflects past underperformance and strategic adjustments, preventing a higher sentiment score.

Positives

• Aims to restore the incentive and retention value of stock options for key employees and directors, which is crucial for retaining talent in a competitive industry.
• Considered a less dilutive approach compared to granting significant additional equity awards to address the issue of underwater options.
• Avoids substantial increases in cash compensation expenses, which would reduce cash on hand and potentially adversely affect business and operating results.
• Seeks to realign the interests of optionholders with those of stockholders, encouraging them to drive long-term value creation and support stock price recovery and growth.
• The Board believes this action is consistent with its approach of orienting long-term incentives toward stock options to minimize incremental dilution.

Negatives

• The necessity of the option repricing highlights a significant prior decline in the company's stock price, rendering a large portion of outstanding options 'underwater' and ineffective as incentives.
• The company recently announced a strategic restructuring, including the deprioritization of Chronic Granulomatous Disease programs and a cost and workforce reduction, indicating operational challenges.
• The repricing could be perceived by some stockholders as a transfer of value from existing shareholders to optionholders, potentially impacting investor sentiment.
• The company acknowledges that if the repricing is not approved, it may need to consider alternative compensation structures, which could lead to increased dilution or cash expenditures.

Risks

• The market price of common stock has historically been volatile, reflecting the inherent risks and uncertainties in the development of product candidates, particularly for a biotechnology company.
• Failure to restore the incentive and retention value of options could undermine long-term commitment and jeopardize the ability to retain critical talent in the extremely competitive biotechnology industry.
• Uncertainty regarding future clinical results and stock price appreciation could continue to impact the effectiveness of equity incentives.
• If the Option Repricing Proposal is not approved, the company may incur additional costs or dilution from alternative compensation structures.
• There is a risk of insufficient votes for the Option Repricing Proposal, which could necessitate adjourning the Special Meeting to solicit additional proxies.

Future Outlook

The company aims to restore incentive value and improve morale among employees and directors to ensure alignment and motivation to execute on its reprioritized strategy, drive value for stockholders, and share in that value going forward. If the Option Repricing is not approved by stockholders, the company may need to consider alternative compensation structures to achieve its objectives of retaining key talent.

Management Comments

• The Board believes that the Option Repricing is in the best interests of the Company and its stockholders, as it provides incentives to retain and motivate the Eligible Optionholders without incurring the stock dilution that would result from significant additional equity grants or additional cash expenditures that would result from additional cash compensation.
• The Board continues to believe in value creation rather than value transfer and views the Option Repricing as consistent with its approach of orienting long-term incentives toward stock options as the primary tool to minimize incremental dilution for stockholders, facilitate employee and director retention as the Company pursues its business strategy, restore the retention value of the Eligible Options, and provide Eligible Optionholders with a more realistic incentive to drive stockholder value creation, thereby supporting the Company's continued focus on stock price recovery and growth.
• We have historically granted stock options under the Plans consistent with the view that stock-based incentive compensation opportunities play a significant role in our ability to attract, motivate and retain qualified individuals who we believe best represent our Company values and can make meaningful contributions towards achieving our purpose of delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying our Prime Editing technology.
• Given the intense competition for experienced and talented individuals with critical and high demand skills in our industry, stock options remain an important part of our incentive compensation.
• The Board determined that adverse changes in the market price of our common stock since the Eligible Options were granted could materially interfere with our efforts to retain the services of the Eligible Optionholders.
• Underwater options may be perceived by their holders as having little or no incentive or retention value due to the disparity between the exercise prices and the current stock price.
• The Board believes that the Option Repricing is in the best interests of the Company and its stockholders, not only to restore the incentive and retentive value of the Eligible Options, but also to improve morale among our employees and directors to ensure alignment and motivation to execute on the Company's reprioritized strategy, drive value for our stockholders, and share in that value going forward.

Industry Context

The biotechnology industry, in which Prime Medicine operates, is characterized by intense competition for experienced and talented individuals with critical and high-demand skills. The sector, along with the broader pharmaceutical market, has experienced extreme price and volume fluctuations, often disproportionate to changes in operating performance, contributing to the challenges faced by companies like Prime Medicine in retaining talent through equity incentives.

Management Changes

Corporate Governance

Related Party Transactions

• The proposed Option Repricing directly benefits current employees, including executive officers, and members of the Board who hold eligible stock options, by reducing their exercise prices.

Stakeholder Impact

• Shareholders: Are asked to approve a measure that could be perceived as a transfer of value to optionholders, but is presented by management as necessary for retention and less dilutive than alternatives, aiming for long-term value creation.
• Employees: Those holding 'underwater' options stand to significantly benefit from the repricing, which is intended to restore their incentive and retention value, improve morale, and align their motivation with the company's strategic goals.
• Directors: Similar to employees, directors holding eligible options will benefit from the repricing, which aims to restore their incentive and retention value and ensure continued alignment with company objectives.

Next Steps

• Hold the Special Meeting of Stockholders on August 1, 2025, to vote on the Option Repricing Proposal and the Adjournment Proposal.
• If the Option Repricing Proposal is approved, the repricing will be implemented effective as of the Repricing Date (the effective date of stockholder approval).
• If the Option Repricing Proposal is not approved, the company will need to consider alternative compensation structures to achieve its retention objectives.
• File a Current Report on Form 8-K with preliminary voting results within four business days following the Special Meeting, and an amendment with final results if not available initially.
• Continue to execute on the company's reprioritized strategy, focusing on the liver franchise and programs funded through external partnerships.

Key Dates

Recommendation

Keywords

Prime Medicine, stock options, option repricing, SEC filing, proxy statement, corporate governance, executive compensation, employee retention, biotechnology, pharmaceutical, stock volatility, shareholder meeting, incentive plans, DEF 14A